Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 289–297 of 297
Dual-pathway obesity therapy amplifies weight loss and metabolic resilience
OrsoBio's mitochondrial protonophore TLC-6740 produced an additional 4.5% weight loss when combined with tirzepatide, alongside improvements in insulin sensitivity and liver health, while demonstrating safety comparable to GLP-1 monotherapy. The approach targets energy expenditure rather than appetite suppression, representing a shift toward dual-pathway obesity treatment and metabolic resilience optimization.
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.
Multi-target ALS therapy targets inflammation and oxidative stress
NeuroSense has secured a South Korean patent for PrimeC, an oral combination therapy targeting neuroinflammation and oxidative stress in ALS, extending intellectual property protection through 2042. Phase 2b data demonstrated disease progression slowing and survival benefit, positioning the candidate for pivotal Phase 3 trials.
BioAge reports positive Phase 1 data for BGE-102
BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.
Lysoway begins Phase 1 trial for neurodegenerative disease treatment
Lysoway Therapeutics has initiated Phase 1 testing of LW-1017, a small-molecule TRPML1 agonist designed to restore autophagy-lysosomal function in neurodegenerative diseases including Alzheimer's and Parkinson's. The compound represents a potential intervention targeting cellular waste clearance mechanisms that decline with age.
BioAge Labs Provides Business Updates
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
United Therapeutics receives RMAT designation for Miroliver ELAP
United Therapeutics received FDA Regenerative Medicine Advanced Therapy designation for Miroliver ELAP, a bioengineered external liver assist device combining a decellularized porcine scaffold seeded with human endothelial and hepatic cells. This designation accelerates development of a bridge therapy for acute liver failure, where 30% of patients currently die due to organ shortage despite potential for spontaneous recovery.
Voyager pushes IV gene therapy for Alzheimer’s
Voyager Therapeutics has demonstrated that engineered gene therapies can reach the brain via intravenous infusion rather than invasive delivery, with preclinical data showing VY1706 achieved safe, predictable distribution to the central nervous system in non-human primates. This addresses a fundamental bottleneck in neurological drug development and positions tau-silencing approaches as candidates for clinical translation in Alzheimer's disease.
Gut Luminal Exosomes in Young and Old Mice: Multi‐Omic Characteristics and Regulation of Gut Permeability
Exosomes in the gut lumen change composition with age, with those from older mice directly impairing barrier integrity and insulin sensitivity in younger recipients, while young exosomes reverse these effects in older mice. This identifies a specific molecular mechanism linking intestinal barrier dysfunction to metabolic aging.